About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 139 results
2011
C. G. Brunstein, Fuchs, E. J., Carter, S. L., Karanes, C., Costa, L. J., Wu, J., Devine, S. M., Wingard, J. R., Aljitawi, O. S., Cutler, C. S., Jagasia, M. H., Ballen, K. K., Eapen, M., and O'Donnell, P. V., “Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.”, Blood, vol. 118, no. 2, pp. 282-8, 2011.
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
M. R. Tomblyn, Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., Horowitz, M. M., Vose, J. M., Negrin, R. S., and Laport, G. G., “Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.”, Biol Blood Marrow Transplant, vol. 17, no. 7, pp. 1051-7, 2011.
D. B. Kohn, Dotti, G., Brentjens, R., Savoldo, B., Jensen, M., Cooper, L. Jn, June, C. H., Rosenberg, S., Sadelain, M., and Heslop, H. E., “CARs on track in the clinic.”, Mol Ther, vol. 19, no. 3, pp. 432-8, 2011.
E. M. Horwitz, Horowitz, M. M., DiFronzo, N. L., Kohn, D. B., and Heslop, H. E., “Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 17, no. 2, pp. 192-6, 2011.
S. M. Devine, Carter, S., Soiffer, R. J., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Stadtmauer, E. A., Alyea, E. P., Keever-Taylor, C. A., and O'Reilly, R. J., “Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot”, Biol Blood Marrow Transplant, vol. 17, no. 9, pp. 1343-51, 2011.
M. A. Pulsipher, Young, N. S., Tolar, J., Risitano, A. M., H Deeg, J., Anderlini, P., Calado, R., Kojima, S., Eapen, M., Harris, R., Scheinberg, P., Savage, S., Maciejewski, J. P., Tiu, R. V., DiFronzo, N., Horowitz, M. M., and Antin, J. H., “Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,”, Biol Blood Marrow Transplant, vol. 17, no. 3, pp. 291-9, 2011.
2010
J. E. Levine, Logan, B., Wu, J., Alousi, A. M., Ho, V., Bolaños-Meade, J., and Weisdorf, D., “Graft-versus-host disease treatment: predictors of survival.”, Biol Blood Marrow Transplant, vol. 16, no. 12, pp. 1693-9, 2010.
P. A. Jacobson, Huang, J., Wu, J., Kim, M., Logan, B., Alousi, A., Grimley, M., Bolaños-Meade, J., Ho, V., Levine, J. E., and Weisdorf, D., “Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 16, no. 3, pp. 421-9, 2010.
J. R. Wingard, Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., Maziarz, R. T., Stadtmauer, E. A., Bolaños-Meade, J., Brown, J., DiPersio, J. F., Boeckh, M., and Marr, K. A., “Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.
2009
A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., “Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.”, Blood, vol. 114, no. 3, pp. 511-7, 2009.
2008
C. Cutler, Stevenson, K., Kim, H. T., Richardson, P., Ho, V. T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J. H., and Soiffer, R., “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
B. Logan, Leifer, E., Bredeson, C., Horowitz, M., Ewell, M., Carter, S., and Geller, N., “Use of biological assignment in hematopoietic stem cell transplantation clinical trials.”, Clin Trials, vol. 5, no. 6, pp. 607-16, 2008.
1996
J. Bruix, Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J. C., Visa, J., Bru, C., and Rodés, J., “Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.”, Gastroenterology, vol. 111, no. 4, pp. 1018-22, 1996.